Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

Sadakatsu Ikeda; Donna E. Hansel; Razelle Kurzrock

doi:10.1016/j.ctrv.2015.06.004

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

Sadakatsu Ikeda, Donna E. Hansel, Razelle Kurzrock

Pathology

Research output: Contribution to journal › Review article › peer-review

13 Scopus citations

Abstract

Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.

Original language	English (US)
Pages (from-to)	699-706
Number of pages	8
Journal	Cancer Treatment Reviews
Volume	41
Issue number	8
DOIs	https://doi.org/10.1016/j.ctrv.2015.06.004
State	Published - Sep 1 2015

Keywords

Genetic aberrations
Immune therapy
Targeted therapy
Urothelial carcinoma

ASJC Scopus subject areas

Oncology
Radiology Nuclear Medicine and imaging

Access to Document

10.1016/j.ctrv.2015.06.004

Cite this

@article{a2b218c161cc4f849fc071a89e626e5d,

title = "Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma",

abstract = "Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.",

keywords = "Genetic aberrations, Immune therapy, Targeted therapy, Urothelial carcinoma",

author = "Sadakatsu Ikeda and Hansel, {Donna E.} and Razelle Kurzrock",

note = "Publisher Copyright: {\textcopyright} 2015 The Authors.",

year = "2015",

month = sep,

day = "1",

doi = "10.1016/j.ctrv.2015.06.004",

language = "English (US)",

volume = "41",

pages = "699--706",

journal = "Cancer Treatment Reviews",

issn = "0305-7372",

publisher = "W.B. Saunders Ltd",

number = "8",

}

TY - JOUR

T1 - Beyond conventional chemotherapy

T2 - Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

AU - Ikeda, Sadakatsu

AU - Hansel, Donna E.

AU - Kurzrock, Razelle

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.

AB - Advanced urothelial carcinoma is frequently lethal, and improvements in cytotoxic chemotherapy have plateaued. Recent technological advances allows for a comprehensive analysis of genomic alterations in a timely manner. The Cancer Genome Atlas (TCGA) study revealed that there are numerous genomic aberrations in muscle-invasive urothelial carcinoma, such as TP53, ARID1A, PIK3CA, ERCC2, FGFR3, and HER2. Molecular targeted therapies against similar genetic alterations are currently available for other malignancies, but their efficacy in urothelial carcinoma has not been established. This review describes the genomic landscape of malignant urothelial carcinomas, with an emphasis on the potential to prosecute these tumours by deploying novel targeted agents and immunotherapy in appropriately selected patient populations.

KW - Genetic aberrations

KW - Immune therapy

KW - Targeted therapy

KW - Urothelial carcinoma

UR - http://www.scopus.com/inward/record.url?scp=84941023230&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941023230&partnerID=8YFLogxK

U2 - 10.1016/j.ctrv.2015.06.004

DO - 10.1016/j.ctrv.2015.06.004

M3 - Review article

C2 - 26138514

AN - SCOPUS:84941023230

SN - 0305-7372

VL - 41

SP - 699

EP - 706

JO - Cancer Treatment Reviews

JF - Cancer Treatment Reviews

IS - 8

ER -

Beyond conventional chemotherapy: Emerging molecular targeted and immunotherapy strategies in urothelial carcinoma

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this